SCD and Alzheimer disease: In support of the disease-promoting impact of SCD1-generated MUFAs in AD, intraventricular infusion with an SCD1 inhibitor reduced the accumulation of MUFA-rich TGs and rescued early NSC dysfunction in periventricular and hippocampal regions in pre-symptomatic 3xTg-AD mice [78].